TNXP READ THE FULL TNXP RESEARCH REPORT Business Update No Advisory Committee Meeting for TNX-102 SL NDA On March 24, 2025, ...

Tonix Pharmaceuticals shares are trading higher by 22.5% during Monday's session. The company announced that the FDA will not ...

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biopharmaceutical company with marketed products and a ...

FDA reviews TNX-102 SL for Fibromyalgia by August 2025, with no advisory required. See why we recommend a buy on TNXP stock.

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 11.27%, which has investors questioning if this is right time to buy.

Tonix Pharmaceuticals (TNXP) announced the launch of TONIX ONE, a fully-integrated digital platform designed to help patients better understand ...

Shares of Tonix Pharmaceuticals (NASDAQ:TNXP) plunged ~21% in the morning hours on Wednesday after the biotech fell short of Street forecasts with its Q4 2024 revenue ahead of a potential FDA nod for ...

The biotechnology sector has experienced a jolt of volatility over the past few days, spearheaded by the dramatic price ...

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.

Tonix Pharmaceuticals Holding Corp.’s TNXP share price has surged by 10.44%, which has investors questioning if this is right ...

On March 24, Tonix Pharmaceuticals Holding announced that the FDA will not require an Advisory Committee meeting for its New ...